Company
GE HealthCare
GADOTERATE MEGLUMINE (gadoterate meglumine) by GE HealthCare is field. First approved in 2022.
Drug data last refreshed 20h ago
field. The magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
Worked on GADOTERATE MEGLUMINE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.